Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant fragment contains a sequence corresponding to a region within amino acids 1 and 210 of RWDD3|
|Purification||Antigen affinity chromatography|
|Storage buffer||0.1M tris glycine, pH 7, with 20% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:500-1:3000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-34884 targets RWDD3 in WB applications and shows reactivity with Human samples.
The PA5-34884 immunogen is recombinant fragment contains a sequence corresponding to a region within amino acids 1 and 210 of RWDD3.
RWDD3 (RSUME), a small RWD-containing protein, has a central role in sumoylation by enhancing SUMO conjugation in the regulatory network of immune-inflammatory signals. RWDD3 increases Ikappa-Beta sumoylation and stability. In addition, RWDD3 inhibits TNF-a-induced kappaB-LUC (Luciferase) reporter activity, showing the functional consequence of Ikappa-Beta increased stability. RSUME-enhanced sumoylation of Ikappa-Beta leads to the inhibition of NF-kappa-Beta activity on two well-known inflammatory genes, IL-8 and cyclooxygenase-2 (Cox-2) and therefore may also favor anti-inflammatory pathways. Expression of RWDD3 was induced under hypoxic conditions and it has a potential role during vascularization. Both BMP-4 and RWDD3 may be interesting targets for inhibiting steps involved in pituitary tumorigenesis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
RSUME; RWD domain-containing sumoylation enhancer; RWD-containing sumoylation enhancer